---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Clinical trials questions"
description: "Clinical trials questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Subgroup results, Study results, and Long-term data. Questions: Does Imbruvica keep working after a dose reduction (RESONATE-2 post hoc analysis)? How much does Imbruvica delay CLL progression vs chlorambucil (RESONATE-2)? Do patients live longer on Imbruvica than chlorambucil (RESONATE-2)? What was the response rate with Imbruvica vs chlorambucil (RESONATE-2)? 16 further questions follow. 20 questions quoted from 15 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Clinical trials questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications](https://www.evicenter.com/medical-information/imbruvica).

## Subgroup results

<a id="imbruvica-dose-reduction-outcomes"></a>

### Does Imbruvica keep working after a dose reduction (RESONATE-2 post hoc analysis)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “This exploratory analysis evaluated baseline demographics and clinical outcomes (PFS) in subgroups of patients with and without dose reductions due to AEs from the overall population of IMBRUVICA<sup>®</sup>-treated CLL patients.”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=This%20exploratory%20analysis%20evaluated%20baseline,CLL%20patients.)

> “Median PFS for IMBRUVICA<sup>®</sup>-treated patients with dose reductions was 87.7 months (95% CI: 56.9-NE) and was not reached (95% CI: 81.9-NE) for those without dose reductions<sup>3</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Median%20PFS%20for,81.9%2DNE%29%20for%20those%20without%20dose)

> “Median follow-up was 82.7 months (range, 0.1-96.6 months). Results from the tail end of the Kaplan-Meier curve should be interpreted with caution due to low number of patients at risk<sup>3</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Median%20follow%2Dup%20was%2082.7%20months,low%20number%20of%20patients%20at)

> “AEs led to dose reductions in 23% (31/135) of all patients treated with IMBRUVICA<sup>®3</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=AEs%20led%20to%20dose%20reductions,of%20all%20patients%20treated%20with)

> “Results are based on a starting dosage of IMBRUVICA<sup>®</sup> 420 mg once daily. Kaplan-Meier curves ≥7.5 years have a limited sample size, potentially impacting PFS estimates”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Results%20are%20based%20on%20a,sample%20size%2C%20potentially%20impacting%20PFS)

> “Subgroups of patients with and without dose modifications were not stratified for any baseline characteristics. Imbalances in baseline characteristics may exist between these groups<sup>3</sup>
> Outcomes in the subgroup of patients with and without dose reductions in the overall population of all IMBRUVICA<sup>®</sup>-treated patients from RESONATE™-2 are from exploratory post hoc analyses and were not powered for significance; comparative statistics are provided for descriptive purposes only<sup>3</sup>
> Dose modifications for any reason were per protocol based on the discretion of the physician<sup>3</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Subgroups%20of%20patients%20with%20and%20without%20dose%20modifications,on%20the%20discretion%20of%20the)

> “8-year RESONATE™-2 long-term dosing results are not included in the Prescribing Information for IMBRUVICA<sup>®</sup>.”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=8%2Dyear%20RESONATE%E2%84%A2%2D2%20long%2Dterm%20dosing%20results,in%20the%20Prescribing%20Information%20for)

<a id="imbruvica-illuminate-high-risk"></a>

### How did high-risk CLL patients do on Imbruvica plus obinutuzumab (iLLUMINATE)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Median follow-up of 31 months<sup>1</sup>”

Source: [IMBRUVICA: iLLUMINATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/illuminate/progression-free-survival#:~:text=Median%20follow%2Dup%20of%2031)

> “At baseline, 65% of patients presented with CLL/SLL high-risk factors:
> Unmutated IGHV (54%), del17p/TP53 mutation (18%), or del11q (15%)
>
> 85% risk reduction of disease progression or death with IMBRUVICA<sup>®</sup> + obinutuzumab in high-risk patients<sup>2</sup>:
>
> Median PFS was not reached with IMBRUVICA<sup>®</sup> + obinutuzumab
> Median PFS was 14.7 months with chlorambucil + obinutuzumab (95% CI: 12.4, 16.9)
>
> Analysis of the high-risk group consisting of unmutated IGHV, del17p/TP53 mutation, del11q was supplemental and not prespecified.”

Source: [IMBRUVICA: iLLUMINATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/illuminate/progression-free-survival#:~:text=At%20baseline%2C%2065%25%20of%20patients,was%20supplemental%20and%20not%20prespecified.)

> “In the high risk CLL/SLL population (del 17p/TP53 mutation, del 11q, or unmutated IGHV), the 
> PFS HR was 0.15 [95% CI (0.09, 0.27)].”

Source: [IMBRUVICA: Prescribing information, page 45, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=45)

Note: The study design paragraph of the same page lists progression-free survival in the high-risk population as a secondary endpoint.

<a id="imbruvica-del17p"></a>

### How effective is Imbruvica for previously treated CLL with 17p deletion (RESONATE)?

Applies to: Adults with previously treated CLL/SLL with 17p deletion

> “RESONATE included 127 patients with del 17p CLL/SLL. The median age was 67 years (range, 
> 30 to 84 years), 62% were male, and 88% were White. All patients had a baseline ECOG 
> performance status of 0 or 1. PFS and ORR were assessed by an IRC.”

Source: [IMBRUVICA: Prescribing information, page 40, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=40)

> “Table 23:  Efficacy Results in Patients with del 17p CLL/SLL in RESONATE 
> Endpoint 
> IMBRUVICA 
> N=63 
> Ofatumumab 
> N=64 
> Progression-Free Survival<sup>a</sup> 
> Number of events (%) 
> 16 (25.4) 
> 38 (59.4) 
>    Disease progression 
> 12  
> 31  
>    Death events  
> 4  
> 7  
> Median (95% CI), months 
> NE 
> 5.8 (5.3, 7.9) 
> HR (95% CI) 
> 0.25 (0.14, 0.45) 
> Overall Response Rate<sup>a</sup> 
> 47.6% 
> 4.7% 
> <sup>a</sup>  IRC evaluated. All partial responses achieved; none of the patients achieved a complete response. 
> CI = confidence interval; HR = hazard ratio; NE = not evaluable.”

Source: [IMBRUVICA: Prescribing information, page 40, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=40)

> “With an overall follow-up of 63 months, the median investigator-assessed PFS in patients with 
> del 17p per IWCLL criteria was 40.6 months [95% CI (25.4, 44.6)] in the IMBRUVICA arm and 
> 6.2 months [95% CI (4.6, 8.1)] in the ofatumumab arm. Overall response rate as assessed by 
> investigators in patients with del 17p was 88.9% in the IMBRUVICA arm versus 18.8% in the 
> ofatumumab arm.”

Source: [IMBRUVICA: Prescribing information, page 40, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=40)

> “Primary analysis for del17p subgroup: IRC-assessed PFS with IMBRUVICA<sup>®</sup> vs ofatumumab with a median follow-up of 9.7 months<sup>1,3</sup>
>
> 75% reduction in risk of disease progression or death<sup>1-3</sup>”

Source: [IMBRUVICA: RESONATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate/progression-free-survival#:~:text=Primary%20analysis%20for%20del17p%20subgroup%3A,risk%20of%20disease%20progression%20or)

## Study results

<a id="imbruvica-resonate2-pfs"></a>

### How much does Imbruvica delay CLL progression vs chlorambucil (RESONATE-2)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Study Design: Phase 3, multicenter, open-label trial of patients with 1L CLL/SLL (N=269), ≥65 years of age who were randomized 1:1 to IMBRUVICA<sup>®</sup> 420 mg once daily until disease progression or unacceptable toxicity (n=136) or chlorambucil (n=133) for up to 12 cycles. Patients with del17p were excluded. The primary endpoint was PFS as assessed by an IRC per iwCLL criteria (primary analysis). OS was a secondary endpoint.”

Source: [IMBRUVICA: RESONATE-2 - Long-Term 10-Year Data, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/long-term-data#:~:text=Study%20Design%3A%20Phase%203%2C%20multicenter%2C,OS%20was%20a%20secondary%20endpoint.)

> “90%
> PFS
> Estimated 18-Month PFS Rate with IMBRUVICA<sup>®</sup>
>
> vs 52% with chlorambucil”

Source: [IMBRUVICA: RESONATE-2 - Long-Term 10-Year Data, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/long-term-data#:~:text=90%25,vs%2052%25%20with%20chlorambucil)

> “Table 24:  Efficacy Results in Patients with CLL/SLL in RESONATE-2 
> Endpoint 
> IMBRUVICA 
> N=136 
> Chlorambucil 
> N=133 
> Progression-Free Survival<sup>a</sup> 
> Number of events (%) 
> 15 (11.0) 
> 64 (48.1) 
>    Disease progression 
> 12  
> 57  
>    Death events  
> 3  
> 7  
> Median (95% CI), months 
> NE 
> 18.9 (14.1, 22.0) 
> HR<sup>b</sup> (95% CI) 
> 0.16 (0.09, 0.28)”

Source: [IMBRUVICA: Prescribing information, page 41, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=41)

> “With an overall follow-up of 55 months, the median PFS was not reached in the IMBRUVICA 
> arm.”

Source: [IMBRUVICA: Prescribing information, page 42, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=42)

<a id="imbruvica-resonate2-survival"></a>

### Do patients live longer on Imbruvica than chlorambucil (RESONATE-2)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “95%
> OS
> Estimated 2-Year OS Rate with IMBRUVICA<sup>®</sup>
>
> (95% CI: 89, 97) vs 84% with chlorambucil (95% CI: 77, 90)
> HR=0.44 (95% CI: 0.21, 0.92) (secondary endpoint)
>
> Median follow-up of 28.1 months
> 41% of chlorambucil-treated patients crossed over to IMBRUVICA<sup>®</sup> upon disease progression”

Source: [IMBRUVICA: RESONATE-2 - Long-Term 10-Year Data, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/long-term-data#:~:text=95%25,upon%20disease%20progression)

> “With a median follow-up of 28.1 months, there were 32 observed death events [11 (8.1%) and 
> 21 (15.8%) in IMBRUVICA and chlorambucil treatment arms, respectively].  With 41% of 
> patients switching from chlorambucil to IMBRUVICA, the overall survival analysis in the ITT 
> patient population resulted in a statistically significant HR of 0.44 [95% CI (0.21, 0.92)] and 
> 2-year survival rate estimates of 94.7% [95% CI (89.1, 97.4)] and 84.3% [95% CI (76.7, 89.6)] 
> in the IMBRUVICA and chlorambucil arms, respectively.”

Source: [IMBRUVICA: Prescribing information, page 41, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=41)

<a id="imbruvica-resonate2-response-rate"></a>

### What was the response rate with Imbruvica vs chlorambucil (RESONATE-2)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Table 24:  Efficacy Results in Patients with CLL/SLL in RESONATE-2 
> Endpoint 
> IMBRUVICA 
> N=136 
> Chlorambucil 
> N=133”

Source: [IMBRUVICA: Prescribing information, page 41, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=41)

> “Overall Response Rate<sup>a</sup> (CR + PR) 
> 82.4% 
> 35.3% 
> P-value 
> <0.0001”

Source: [IMBRUVICA: Prescribing information, page 41, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=41)

> “<sup>a</sup>  IRC evaluated; five subjects (3.7%) in the IMBRUVICA arm and two subjects (1.5%) in the Chlorambucil arm achieved 
> complete response.”

Source: [IMBRUVICA: Prescribing information, page 41, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=41)

<a id="imbruvica-e1912-pfs"></a>

### How much does Imbruvica plus rituximab delay progression vs FCR (E1912)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “E1912 was an open-label, phase 3 trial in treatment-naïve patients (N=529) with CLL/SLL ≤70 years of age, randomized 2:1 to receive IMBRUVICA<sup>®</sup>* + rituximab<sup>†</sup> (n=354) or FCR<sup>‡§</sup> (n=175). Patients with del17p were excluded. The primary endpoint was PFS as assessed by an IRC per iwCLL criteria.”

Source: [IMBRUVICA: E1912 - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/e1912/progression-free-survival#:~:text=E1912%20was%20an%20open%2Dlabel%2C%20phase,an%20IRC%20per%20iwCLL%20criteria.)

> “At a median follow-up of 37 months, 41 events (12%) occurred in the IMBRUVICA<sup>®</sup> + rituximab arm and 44 events (25%) occurred in the FCR arm<sup>1</sup>”

Source: [IMBRUVICA: E1912 - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/e1912/progression-free-survival#:~:text=At%20a%20median%20follow%2Dup%20of,%2825%25%29%20occurred%20in%20the%20FCR)

> “Table 27:  Efficacy Results in Patients with CLL/SLL in E1912 
> Endpoint 
> IMBRUVICA + R  
> N=354 
> FCR 
> N=175 
> Progression-Free Survival 
> Number of events (%) 
> 41 (12) 
> 44 (25) 
>    Disease progression 
> 39 
> 38 
>    Death events  
> 2 
> 6 
> Median (95% CI), months 
> NE (49.4, NE) 
> NE (47.1, NE) 
> HR (95% CI) 
> 0.34 (0.22, 0.52) 
> P-value<sup>a</sup> 
> <0.0001 
> <sup>a</sup> P-value is from unstratified log-rank test. 
> FCR = fludarabine, cyclophosphamide, and rituximab; HR = hazard ratio; R = rituximab; NE = not evaluable.”

Source: [IMBRUVICA: Prescribing information, page 46, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=46)

Note: FCR is fludarabine, cyclophosphamide, and rituximab.

<a id="imbruvica-e1912-survival"></a>

### What were the overall survival results for Imbruvica plus rituximab vs FCR (E1912)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “E1912: median OS was not reached in either arm<sup>1</sup>
> OS with median follow-up of 49 months<sup>1</sup>”

Source: [IMBRUVICA: E1912 - Overall Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/e1912/overall-survival#:~:text=E1912%3A%20median%20OS%20was%20not,with%20median%20follow%2Dup%20of%2049)

> “With a median follow-up time on study of 49 months, median overall survival was not reached 
> with a total of 23 deaths: 11 (3%) in the IMBRUVICA plus rituximab and 12 (7%) in the FCR 
> treatment arms.”

Source: [IMBRUVICA: Prescribing information, page 47, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=47)

Note: FCR is fludarabine, cyclophosphamide, and rituximab.

<a id="imbruvica-illuminate-pfs"></a>

### How much does Imbruvica plus obinutuzumab delay progression vs chlorambucil-obinutuzumab (iLLUMINATE)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Phase 3, multicenter, open-label trial of 1L CLL/SLL patients ≥65 years or 1L CLL/SLL patients <65 years of age with at least one of the following conditions: coexisting medical conditions, reduced renal function as measured by creatinine clearance <70 mL/min, or del17p/TP53 mutation (N=229). Patients were randomized 1:1 to IMBRUVICA<sup>®</sup> 420 mg once daily until disease progression or unacceptable toxicity in combination with obinutuzumab (n=113) or chlorambucil in combination with obinutuzumab (n=116). The primary endpoint was progression-free survival. The secondary endpoints were progression-free survival in the high-risk population (unmutated IGHV, del17p/TP53 mutation, or del11q) and overall response rate.”

Source: [IMBRUVICA: iLLUMINATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/illuminate/progression-free-survival#:~:text=Phase%203%2C%20multicenter%2C%20open%2Dlabel%20trial,del11q%29%20and%20overall%20response%20rate.)

> “Median follow-up of 31 months<sup>1</sup>
> 77% reduction in risk of disease progression or death with IMBRUVICA<sup>®</sup> + obinutuzumab<sup>1,2</sup>”

Source: [IMBRUVICA: iLLUMINATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/illuminate/progression-free-survival#:~:text=Median%20follow%2Dup%20of%2031,disease%20progression%20or%20death%20with)

> “Table 26:  Efficacy Results in Patients with CLL/SLL in iLLUMINATE 
> Endpoint 
> IMBRUVICA + 
> Obinutuzumab 
> N=113 
> Chlorambucil + 
> Obinutuzumab 
> N=116 
> Progression-Free Survival<sup>a</sup> 
> Number of events (%) 
> 24 (21) 
> 74 (64) 
>    Disease progression 
> 11 
> 64 
>    Death events  
> 13 
> 10 
> Median (95% CI), months 
> NE 
> 19.0 (15.1, 22.1) 
> HR (95% CI) 
> 0.23 (0.15, 0.37) 
> P-value<sup>b</sup> 
> <0.0001”

Source: [IMBRUVICA: Prescribing information, page 44, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=44)

> “<sup>b</sup> P-value is from unstratified log-rank test.”

Source: [IMBRUVICA: Prescribing information, page 44, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=44)

<a id="imbruvica-illuminate-response-rate"></a>

### What was the response rate with Imbruvica plus obinutuzumab (iLLUMINATE)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Median follow-up was 31 months<sup>1</sup>
> 88.5% ORR with IMBRUVICA<sup>®</sup> + obinutuzumab vs 73% with chlorambucil + obinutuzumab<sup>1</sup>
> 19.5% of patients in the IMBRUVICA<sup>®</sup> + obinutuzumab arm achieved a complete response*
> 7.8% of patients in the chlorambucil + obinutuzumab arm achieved a complete response
> 69.0% of patients in the IMBRUVICA<sup>®</sup> + obinutuzumab arm achieved a partial response<sup>†</sup>
> 65.5% of patients in the chlorambucil + obinutuzumab arm achieved a partial response”

Source: [IMBRUVICA: iLLUMINATE - Overall Response Rate, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/illuminate/overall-response-rate#:~:text=Median%20follow%2Dup%20was%2031,chlorambucil%20%2B%20obinutuzumab%20arm%20achieved%20a%20partial%20response)

> “Includes 1 patient in the IMBRUVICA<sup>®</sup> + obinutuzumab arm with a complete response with incomplete marrow recovery (CRi).”

Source: [IMBRUVICA: iLLUMINATE - Overall Response Rate, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/illuminate/overall-response-rate#:~:text=Includes%201%20patient%20in%20the,with%20incomplete%20marrow%20recovery%20%28CRi%29.)

<a id="imbruvica-alliance-survival"></a>

### Imbruvica vs bendamustine-rituximab: did survival differ in ALLIANCE A041202?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Alliance was an open-label, phase 3 trial (N=547) with CLL/SLL ≥65 years of age. Three treatment arms were assessed: IMBRUVICA<sup>®</sup> 420 mg (n=182), IMBRUVICA<sup>®</sup> 420 mg + rituximab (n=182), and bendamustine + rituximab (n=183). In the I and I+R arm, IMBRUVICA<sup>®</sup> 420 mg was taken once daily until disease progression or unacceptable toxicity. In the I+R arm, rituximab was administered at 375 mg/m<sup>2</sup> weekly for 4 weeks starting on day 1 of cycle 2, then day 1 of cycles 3 to 6 (28 days each). In the B+R arm, rituximab was administered at 375 mg/m<sup>2</sup> on day 0 of cycle 1, then 500 mg/m<sup>2</sup> on day 1 of cycles 2 to 6 (28 days each) and bendamustine was administered at 90 mg/m<sup>2</sup> days 1 and 2 each 28-day cycle for 6 cycles. The primary endpoint was PFS as assessed by investigators per iwCLL criteria.”

Source: [IMBRUVICA: ALLIANCE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/alliance/progression-free-survival#:~:text=Alliance%20was%20an%20open%2Dlabel%2C%20phase,by%20investigators%20per%20iwCLL%20criteria.)

> “These data have not been reviewed by the FDA and are not included in the IMBRUVICA<sup>®</sup> Prescribing Information.”

Source: [IMBRUVICA: ALLIANCE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/alliance/progression-free-survival#:~:text=These%20data%20have%20not%20been,Prescribing%20Information.)

> “With a median follow-up of 38 months, there were no significant differences in OS among the arms (P≥0.65 for all pairwise comparison). 30 patients treated with BR crossed over to IMBRUVICA<sup>®</sup> monotherapy within 1 year after disease progression.<sup>1</sup>”

Source: [IMBRUVICA: ALLIANCE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/alliance/progression-free-survival#:~:text=With%20a%20median%20follow%2Dup%20of,within%201%20year%20after%20disease)

<a id="imbruvica-cll17-pfs"></a>

### Imbruvica vs venetoclax plus obinutuzumab: how did progression-free survival compare (CLL17)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “CLL17 is a Phase 3, noninferiority study comparing fixed-duration combination therapies to continuous IMBRUVICA<sup>®</sup> monotherapy<sup>1-3</sup>”

Source: [IMBRUVICA: RESONATE-2 - CLL17 Study, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/cll17-study#:~:text=CLL17%20is%20a%20Phase%203%2C,fixed%2Dduration%20combination%20therapies%20to%20continuous)

> “This is a prespecified interim analysis with still maturing follow up.
>
> The CLL17 study is not included in the Prescribing Information for IMBRUVICA<sup>®</sup>.
>
> Data are descriptive and provided for informational purposes.
>
> The trial was designed to evaluate for noninferiority (limits claims of superiority/inferiority).”

Source: [IMBRUVICA: RESONATE-2 - CLL17 Study, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/cll17-study#:~:text=This%20is%20a%20prespecified%20interim,noninferiority%20%28limits%20claims%20of%20superiority%2Finferiority%29.)

> “THE PRIMARY ENDPOINT WAS INVESTIGATOR-ASSESSED PFS, WITH AN NI MARGIN FOR HR OF 1.608 (CORRESPONDING TO AN NI MARGIN OF 8% AT 3 YEARS).”

Source: [IMBRUVICA: RESONATE-2 - CLL17 Study, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/cll17-study#:~:text=THE%20PRIMARY%20ENDPOINT%20WAS%20INVESTIGATOR%2DASSESSED,OF%208%25%20AT%203%20YEARS%29.)

> “Data Limitations
> CLL17 efficacy results are not included in the Prescribing Information for IMBRUVICA<sup>®2</sup>
> The open-label nature of the study could introduce bias<sup>3</sup>
> Racial/ethnic demographics may be skewed by an all-European trial<sup>3</sup>
> This is an interim analysis with still maturing follow up (median observation time was 34.2 months)<sup>1</sup>
> Median follow-up was 34.2 months for both treatment arms<sup>1</sup>
> Median 3-year PFS was 81.0% for IMBRUVICA<sup>®</sup> vs 81.1% for venetoclax + obinutuzumab<sup>1</sup>
> Upper limit of adjusted CI below predefined margin, supporting noninferiority (HR=1.608)<sup>1</sup>”

Source: [IMBRUVICA: RESONATE-2 - CLL17 Study, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/cll17-study#:~:text=Data%20Limitations,below%20predefined%20margin%2C%20supporting%20noninferiority)

Note: CLL17 is an investigator-initiated trial that the CLL17 page of the Imbruvica HCP site cites (Al-Sawaf et al., N Engl J Med 2025). These passages report the Imbruvica and venetoclax plus obinutuzumab arms. 1.608 is the prespecified noninferiority margin for the hazard ratio; the page does not state the observed hazard ratio.

<a id="imbruvica-resonate-pfs"></a>

### How effective is Imbruvica vs ofatumumab in relapsed CLL (RESONATE)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Phase 3, multicenter, open-label trial of previously treated CLL/SLL (N=391). Patients with del17p were included (n=127). Patients were randomized 1:1 to IMBRUVICA<sup>®</sup> 420 mg once daily until disease progression or unacceptable toxicity (n=195) or IV ofatumumab for up to 12 doses (n=196). Patients on ofatumumab were able to cross over to IMBRUVICA<sup>®</sup> upon disease progression. Progression-free survival was the primary endpoint. Overall response rate and overall survival were secondary endpoints.”

Source: [IMBRUVICA: RESONATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate/progression-free-survival#:~:text=Phase%203%2C%20multicenter%2C%20open%2Dlabel%20trial,overall%20survival%20were%20secondary%20endpoints.)

> “Primary analysis with a median IRC-assessed follow-up of 9.4 months<sup>2</sup>
> 78% statistically significant reduction in risk of progression or death<sup>1,2</sup>
> Median PFS not reached for IMBRUVICA<sup>®</sup> vs 8.1 months (95% CI: 7.2, 8.3) with ofatumumab<sup>1,2</sup>”

Source: [IMBRUVICA: RESONATE - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate/progression-free-survival#:~:text=Primary%20analysis%20with%20a%20median,%2895%25%20CI%3A%207.2%2C%208.3%29%20with)

> “Table 22:  Efficacy Results in Patients with CLL/SLL in RESONATE 
> Endpoint 
> IMBRUVICA 
> N=195 
> Ofatumumab 
> N=196 
> Progression-Free Survival<sup>b</sup> 
>
> Number of events (%) 
> 35 (17.9) 
> 111 (56.6)  
>    Disease progression 
> 26 
> 93 
>    Death events 
> 9 
> 18 
> Median (95% CI), months 
> NE 
> 8.1 (7.2, 8.3) 
> HR (95% CI) 
> 0.22 (0.15, 0.32) 
> Overall Survival<sup>a</sup> 
>
> Number of deaths (%) 
> 16 (8.2) 
> 33 (16.8) 
> HR (95% CI) 
> 0.43 (0.24, 0.79) 
> Overall Response Rate<sup>b</sup> 
> 42.6% 
> 4.1% 
> <sup>a</sup> Median OS not evaluable for either arm. 
> <sup>b</sup> IRC evaluated. All partial responses achieved; none of the patients achieved a complete response. 
> CI = confidence interval; HR = hazard ratio; NE = not evaluable.”

Source: [IMBRUVICA: Prescribing information, page 38, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=38)

> “With an overall follow-up of 63 months, the median investigator-assessed PFS per IWCLL 
> criteria was 44.1 months [95% CI (38.5, 56.9)] in the IMBRUVICA arm and 8.1 months 
> [95% CI (7.8, 8.3)] in the ofatumumab arm. Overall response rate as assessed by investigators 
> was 87.2% in the IMBRUVICA arm versus 22.4% in the ofatumumab arm.”

Source: [IMBRUVICA: Prescribing information, page 40, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=40)

<a id="imbruvica-resonate-survival"></a>

### Does Imbruvica improve survival vs ofatumumab in relapsed CLL (RESONATE)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Primary analysis: IMBRUVICA<sup>®</sup> achieved a 57% statistically significant reduction in the risk of death<sup>1,2</sup>
> Median follow-up was 9.4 months<sup>2</sup>
> Median OS not evaluable in either treatment arm<sup>1</sup>
>
> 57 patients randomized to ofatumumab crossed over following disease progression to receive IMBRUVICA<sup>®1</sup>”

Source: [IMBRUVICA: RESONATE - Overall Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate/overall-survival#:~:text=Primary%20analysis%3A,following%20disease%20progression%20to%20receive)

> “Overall Survival<sup>a</sup> 
>
> Number of deaths (%) 
> 16 (8.2) 
> 33 (16.8) 
> HR (95% CI) 
> 0.43 (0.24, 0.79)”

Source: [IMBRUVICA: Prescribing information, page 38, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=38)

> “<sup>a</sup> Median OS not evaluable for either arm.”

Source: [IMBRUVICA: Prescribing information, page 38, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=38)

<a id="imbruvica-resonate-response-rate"></a>

### What was the response rate with Imbruvica vs ofatumumab (RESONATE)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “ORR was assessed by an IRC per iwCLL criteria.<sup>1-4</sup>
>
> Median follow-up was 9.4 months<sup>2</sup>
> None of the patients achieved a complete response<sup>1</sup>
>
> ORR in patients with relapsed/refractory del 17p CLL/SLL<sup>1</sup>
>
> Median follow-up was 9.7 months<sup>5</sup>
> The ORR in patients with previously treated del 17p CLL/SLL receiving IMBRUVICA<sup>®</sup> (n=63) was 48% vs 5% with ofatumumab (n=64). All responses were partial responses<sup>1</sup>
>
> Long-term investigator-assessed follow-up<sup>1</sup>
>
> With an overall follow-up of 63 months, the ORR as assessed by investigators was 87.2% in the IMBRUVICA<sup>®</sup> arm versus 22.4% in the ofatumumab arm<sup>1</sup>
> With an overall follow-up of 63 months, the ORR as assessed by investigators in patients with del 17p was 88.9% in the IMBRUVICA<sup>®</sup> arm versus 18.8% in the ofatumumab arm<sup>1</sup>”

Source: [IMBRUVICA: RESONATE - Overall Response Rate, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate/overall-response-rate#:~:text=ORR%20was%20assessed%20by%20an,versus%2018.8%25%20in%20the%20ofatumumab)

> “Overall Response Rate<sup>b</sup> 
> 42.6% 
> 4.1%”

Source: [IMBRUVICA: Prescribing information, page 38, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=38)

<a id="imbruvica-helios-pfs"></a>

### Does adding Imbruvica to bendamustine-rituximab delay progression (HELIOS)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Phase 3, multicenter, double blind, placebo-controlled trial of previously treated CLL/SLL patients (N=578). Patients were randomized 1:1 to IMBRUVICA<sup>®</sup> 420 mg once daily until disease progression or unacceptable toxicity in combination with BR for up to six 28-day cycles (n=289) or a placebo once daily until disease progression or unacceptable toxicity in combination with BR for up to six 28-day cycles (n=289). Patients on placebo were able to cross over to IMBRUVICA<sup>®</sup> after confirmed disease progression. The primary endpoint was progression-free survival. The secondary endpoint was overall response rate.”

Source: [IMBRUVICA: HELIOS - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/helios/progression-free-survival#:~:text=Phase%203%2C%20multicenter%2C%20double%20blind%2C,endpoint%20was%20overall%20response%20rate.)

> “80% statistically significant reduction in risk of progression or death<sup>1,2</sup>
> Median follow-up was 17 months (13.7-20.7; N=579)<sup>2</sup>
> Median PFS not evaluable with IMBRUVICA<sup>®</sup> + BR vs 13.3 months (95% CI: 11.3, 13.9) with placebo + BR<sup>1</sup>
> 31% of patients crossed over from placebo to IMBRUVICA<sup>®</sup> upon disease progression<sup>2</sup>”

Source: [IMBRUVICA: HELIOS - Progression-Free Survival, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/helios/progression-free-survival#:~:text=80%25%20statistically%20significant%20reduction%20in,upon%20disease)

> “Table 25:  Efficacy Results in Patients with CLL/SLL in HELIOS 
> Endpoint 
> IMBRUVICA + BR 
> N=289 
> Placebo + BR 
> N=289 
> Progression-Free Survival<sup>a</sup> 
> Number of events (%) 
> 56 (19.4) 
> 183 (63.3) 
> Median (95% CI), months 
> NE 
> 13.3 (11.3, 13.9) 
> HR (95% CI) 
> 0.20 (0.15, 0.28)”

Source: [IMBRUVICA: Prescribing information, page 43, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=43)

<a id="imbruvica-helios-response-rate"></a>

### What was the response rate with Imbruvica plus bendamustine-rituximab (HELIOS)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Secondary endpoint: Overall response rate IMBRUVICA<sup>®</sup> + BR vs placebo + BR (N=578)<sup>1,2</sup>”

Source: [IMBRUVICA: HELIOS - Overall Response Rate, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/helios/overall-response-rate#:~:text=Secondary%20endpoint%3A%20Overall%20response%20rate,BR%20vs%20placebo%20%2B%20BR)

> “Median follow-up was 17 months (N=578)<sup>2</sup>
> ORR (complete response and partial response) was assessed by an IRC per iwCLL criteria<sup>2-4</sup>
> 8.3% of patients who received IMBRUVICA<sup>®</sup> + BR achieved complete response vs 2.1% of patients who received placebo + BR<sup>1</sup>”

Source: [IMBRUVICA: HELIOS - Overall Response Rate, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/helios/overall-response-rate#:~:text=Median%20follow%2Dup%20was%2017%20months,of%20patients%20who%20received%20placebo)

> “Overall Response Rate<sup>a</sup> 
> 82.7% 
> 67.8%”

Source: [IMBRUVICA: Prescribing information, page 43, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=43)

<a id="imbruvica-study-1102"></a>

### What was the response rate with Imbruvica alone in Study 1102 (previously treated CLL)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Study 1102 (NCT01105247), an open-label, multi-center trial, was conducted in 48 previously 
> treated CLL patients. IMBRUVICA was administered orally at 420 mg once daily until disease 
> progression or unacceptable toxicity. The ORR and DOR were assessed using a modified version 
> of the International Workshop on CLL Criteria by an Independent Review Committee.  
> The median age was 67 years (range, 37 to 82 years), 71% were male, and 94% were White. All 
> patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 
> 80 months and the median number of prior treatments was 4 (range, 1 to 12 treatments). At 
> baseline, 46% of subjects had at least one tumor ≥ 5 cm.”

Source: [IMBRUVICA: Prescribing information, page 37, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=37)

> “The ORR was 58.3% (95% CI: 43.2%, 72.4%), all partial responses. None of the patients 
> achieved a complete response. The DOR ranged from 5.6 to 24.2+ months. The median DOR 
> was not reached.”

Source: [IMBRUVICA: Prescribing information, page 38, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=38)

## Long-term data

<a id="imbruvica-resonate2-10-year"></a>

### What are the up to 10-year follow-up results of Imbruvica in RESONATE-2?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Data Limitations: 10-year RESONATE™-2 long-term efficacy results are not included in the Prescribing Information for IMBRUVICA<sup>®</sup>. The timing for
> long-term follow-up was not prespecified, and the analysis was descriptive in nature.”

Source: [IMBRUVICA: RESONATE-2 - Long-Term 10-Year Data, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/long-term-data#:~:text=Data%20Limitations%3A%2010%2Dyear%20RESONATE%E2%84%A2%2D2%20long%2Dterm,analysis%20was%20descriptive%20in%20nature.)

> “Median follow-up for patients in the IMBRUVICA<sup>®</sup> arm for all efficacy endpoints was 9.6 years (115.0 months [range 0.1-122.8])
> 68%
> OS
> Estimated OS at 9 years with IMBRUVICA<sup>®</sup>
>
> Long-term OS analysis<sup>3</sup>
>
> Median OS was not reached in the IMBRUVICA<sup>®</sup> arm”

Source: [IMBRUVICA: RESONATE-2 - Long-Term 10-Year Data, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/long-term-data#:~:text=Median%20follow%2Dup%20for%20patients%20in,arm)

> “50%
> PFS
> Estimated PFS at 9 years with
> IMBRUVICA<sup>®</sup> vs 4% with chlorambucil
>
> Long-term PFS analysis (investigator assessed)<sup>3</sup>
>
> With up to 10 years of follow-up, median PFS for IMBRUVICA<sup>®</sup> was 8.9 years (95% CI: 7.0, NE) vs 1.3 years (95% CI: 0.9, 1.6) with chlorambucil<sup>3</sup>
> For patients in the chlorambucil arm, median follow-up was 5.6 years (66.7 months [range 0.1-118.4 months])<sup>3,4</sup>”

Source: [IMBRUVICA: RESONATE-2 - Long-Term 10-Year Data, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/long-term-data#:~:text=50%25,years%20%2866.7%20months%20%5Brange%200.1%2D118.4)

Note: The 10-year results are from the final RESONATE-2 analysis that the page cites as data on file and an unpublished abstract.

## Clinical trials

<a id="imbruvica-resonate2-patients"></a>

### Who was enrolled in the Imbruvica RESONATE-2 trial?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “PATIENTS ≥65 YEARS WITH TREATMENT- NAÏVE CLL/SLL
>
> (N=269)
>
> 1:1
>
> RANDOMIZATION
>
> IMBRUVICA<sup>®</sup> 420 mg once daily until disease progression or unacceptable toxicity (n=136)
>
> Chlorambucil for up to 12 cycles<sup>*†</sup> (n=133)”

Source: [IMBRUVICA: RESONATE-2 - Study Design, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/study-design#:~:text=PATIENTS%20%E2%89%A565%20YEARS%20WITH%20TREATMENT%2D,%28n%3D133%29)

> “GENDER & RACE
>
> Male: 63%; White: 91%
>
> AGE
>
> Median: 73 years
>
> Range: 65-90 years
>
> ECOG PS
>
> 0-1: 91%
>
> 2: 9%
>
> RAI STAGE 3 OR 4
>
> 0, I, II: 55%
>
> III, IV: 45%
>
> PATIENTS IN RESONATE™-2 (N=269)
>
> MUTATION STATUS
>
> TP53:
>
> Yes: 5%
>
> No: 76%
>
> Unknown: 19%
>
> IGHV:
>
> Mutated: 32%
>
> Unmutated: 44%
>
> Unknown: 24%
>
> CHROMOSOME 11Q22.3 DELETION
>
> Yes: 20%
>
> No: 73%
>
> Unknown: 7%
>
> Patients with del17p were excluded”

Source: [IMBRUVICA: RESONATE-2 - Study Design, captured 2026-11-13](https://www.imbruvicahcp.com/cll/efficacy/resonate-2/study-design#:~:text=GENDER%20%26%20RACE,Patients%20with%20del17p%20were%20excluded)

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Indication](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication)
- [Safety](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines)
